ROTTERDAM, Netherlands (December 13, 2024) – IMCD NV (“IMCD” or “Company”), a leading global distribution partner and formulator of specialty chemicals and ingredients, today announces that IMCD has signed an agreement to acquire the ingredients distributor business food and nutraceuticals: Daoqin Biological Technology (Shanghai) Co., Ltd., Longyu International Trade (Shanghai) Co., Ltd. and Long’en Biotechnology (Guangzhou) Co., Ltd. in China (jointly “Daoqin”).
Established in 2011, Daoqin specializes in the distribution of functional nutrition, nutraceutical and food ingredients. Daoqin represents leading suppliers and, through its dedicated technical team and laboratory, offers innovative solutions to its customers in the food, personal care and pharmaceutical industries. Daoqin is headquartered in Shanghai, China, and generated revenue of approximately CNY 122 million (approximately €16 million) in 2023 with 21 employees.
“The addition of Daoqin marks another step in our journey to deepen our presence in the food and nutrition markets and broaden the scope of our life sciences business portfolio,” remarked Nicky Huang, general manager of IMCD China. “With the acquisition of Daoqin, we are very pleased to welcome a highly committed and talented team and leverage our complementary portfolios and technical expertise to enhance our capabilities and offering in the local market,” concluded Huang .
“The Daoqin team is excited to join IMCD, as we believe there are strong synergies between our businesses and capabilities,” said Jack Ning, Managing Director of Daoqin. “By leveraging IMCD’s exceptional global network and resources, we look forward to bringing greater innovation and value to customers in China’s life sciences markets.”
Closing of the transaction is subject to customary closing conditions and is expected to occur in the second quarter of 2025.
Attached, the complete press release in PDF format, the main caption of the visual and the photo.